Why the study?
Does rosiglitazone improve myocardial diastolic function compared to glimepiride in metformin-treated type 2 diabetic patients without overt heart disease?
Does rosiglitazone improve myocardial diastolic function compared to glimepiride in metformin-treated type 2 diabetic patients without overt heart disease?
In type 2 diabetic patients without overt cardiovascular disease, rosiglitazone improves diastolic function and reduces oxidative stress compared to glimepiride.
No takes yet. Share an insight, caveat, or question.
May support diastolic preservation in metformin-treated T2DM without overt CVD; extends RCT evidence of rosiglitazone's pleiotropic effects versus glimepiride.
Bibra et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: